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MECHANISM-BASED INHIBITION OF CYP2D6 BY PAROX- 
ETINE. K.M. Bertelsen, K. Venkatakrishnan, L.L. von Moltke, R. 
Scott Obach, and D.J. Greenblatt. Tufts University, Boston, MA and 
Pfizer Inc., Groton, CT. 
The selective serotonin reuptake inhibitor paroxetine (PX) is a 
potent CYP2D6 inhibitor, but the mechanism of inhibition is not 
established, inhibition of CYP2D6 in vitro by PX, fluoxetine (FLU) 
and quinidine (Q) was studied in human liver microsomes (HLM) 
using dextromethorphan O-demethylation (25 IxM) as the index re- 
action. Without preincubation of HLM with inhibitor, mean ICso 
values were: 2.5 ~M for PX, 0.2 jxM for FLU, and 0.23 ixM for Q. 
Preincubation of inhibitor with HLM significantly reduced the PX 
ICso by eight-fold to 0.3 ~M; in contrast, the ICso for FLU and Q 
were actually increased (to 0.42 txM and 0.36 p~M, respectively). PX 
produced time-dependent i activation, with an apparent rate constant 
of 0.17/min based on a Kitz-Wilson plot. This was not true for FLU 
or Q. Incubation of PX with recombinant CYP2D6 yielded a differ- 
ence spectrum with maximum absorbance at 456 nm, and a time- 
dependent increase in absorbance, consistent with inactivation via 
formation of a carbene-heme complex. Thus PX, unlike FLU and Q, 
appears to inhibit CYP2D6 at least in part through a mechanism- 
based process, probably attributable to the methylenedioxy substitu- 
ent of PX. 
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PHARMACOGENOMIC STUDIES USING PARAFFIN EM- 
BEDDED TUMOR SAMPLES. J. M. Rae, Plfl), J. Scheys, BS, 
K. E. Cordero, BS, M. D. Johnson, PhD, University of Michigan, 
Georgetown University, Ann Arbor, MI. 
Paraffin embedded tumor samples are valuable in the study of 
cancer. Besides use in routine staging and marker analysis, they are 
used to test new prognostic and predictive markers. However, their 
use in retrospective pharmacogenomic analysis of clinical trials has 
yet to be evaluated. We set out to establish genotypiug methods for 
polymorphic CYP450s in formalin-fixed archival tumor samples and 
determine if fixation, processing or somatic changes in the tumor 
affect our ability to determine germ-line mutations. To establish the 
assay, paraffin blocks were made from 8 cell lines. DNA from cell 
cultures and paraffin sections was purified using the Qiagen system. 
These samples were genotyped for CYP2C8, CYP2C9, CYP2CI9 
and CYP2D6 alleles using PCR-RFLP. This allowed optimization of 
DNA extraction and genotyping for these materials and showed that 
fixation and processing did not significantly alter the genotypes 
obtained (>97% concordance: cell lines vs paraffin sections). Next, 
sections were cut from archival tumor blocks from t0 patients for 
whom gDNA from peripheral blood was available. Again, concor- 
dance was very high with the same genotype being obtained for 97% 
of the ,alleles tested. Conclusions: accurate genetic testing for poly- 
morphisms on CYP2Cs and CYP2D6 can be obtained from archival 
paraffin embedded tumor samples. Thus, pharmacogenetic analysis 
can be applied to existing cancer therapy trials to test associations 
between these polymorphisms and treatment response. 
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SULFOTRANSFERASE (SULT) 1AI PHARMACOGENETICS: 
FUNCTIONAL 5'-FLANKING REGION (5'-FR) POLYMOR- 
PHISMS. J. Prondzinski, B. Thomae, L. Wang, B. Eckloff, E. 
Wieben, PhD, R. Weinshilboum, MD, Mayo Clinic, Mayo Graduate 
School-Mayo Clinic, Rochester, MN. 
SULTtA1 catalyzes the sulfate conjugation of many drugs, xeno- 
biotics and hormones. Human platelet SULT1A1 activity and thermal 
stability vary widely among individuals and are regulated by inher- 
itance. A single nucleotide polymorphism (SNP) in the SULT1A1 
open reading frame (ORF) (Arg213His) is associated with low levels 
of enzyme activity and thermal stability. However, not all SULT1A1 
phenotypic variation is explained by this SNP. We set out to deter- 
mine whether polymorphisms in the 5'-FR also influence SULT1A1 
expression. We resequenced 2 kb of the SULTIA1 5'-FR using 32 
DNA samples selected for extreme platelet activity and thermal 
stability. Three common SNPs were observed (-1985 C/G, -624 C/G, 
-397 G/A - numbered relative to the "A" in the ATG codon). The 
-624 and -397 SNPs were associated with SULTIAI ORF genotype 
and with platelet SULT1A1 phenotype. Luciferase reporter gene 
constructs containing these SNPs were used to transfect HepG2 cells. 
There was a 59% average decrease in activity (N=9) for the construct 
containing (-624, -397) GA as compared with CG, and a 90.5% 
average decrease in activity (N=9) for a shorter construct that con- 
tained only (-397) A vs. G. These results indicate that 5'-FR genetic 
polymorphisms may contribute to SULT1A1 pharmacogenetic vari- 
ation and that inherited variation in the regulation of transcription 
could influence sulfate conjugation catalyzed by this isoform. 
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INFLUENCE OF CYP2D6 GENOTYPE ON THE QTc INTER- 
VAL AND PLASMA CONCENTRATIONS OF THIORIDAZINE 
AND ITS METABOLITES IN PSYCHIATRIC PATIENTS TAK- 
ING CHRONIC THERAPY. R. Thanacoody, MRCP, A. K. Daly, 
PhD, S. H. Thomas, MD, University of Newcastle, Newcastle, United 
Kingdom (Great Britain). 
Purpose. The antipsychotic agent thioridazine is an important 
cause of QTc interval prolongation and torsade de pointes and 
CYP2D6 is important in its metabolism. This study was performed to 
determine whether CYP2D6 genotype influences the QTc interval in 
long-term recipients of thioridazine. 
Methods: Patients receiving stable doses of thioridazine were 
recruited from psychiatric hospitals and clinics. A 12-lead ECG was 
recorded and the QTc interval measured using a digitiser. CYP2D6 
genotyping was performed for 4 common allelic variants associated 
with absence of activity (*3, *4, *5 and *6). When available, plasma 
was analysed for concentrations of thioridazine and its metabolites, 
thioridazine-2-sulfoxide (T-2SO), thioridazine-2-sulfone (T-SO2), 
and thioridazine-5-sulfoxide (T-5SO) using high performance liquid 
chromatography. 
Results: Genotyping indicated that the 93 patients studied in- 
cluded 54 extensive metabolizers (EM), 30 intermediate metabotizers 
(1M, heterozygotes with 1 mutant allele) and 9 poor metabolizers 
(PM, 2 mutant alleles). The mean doses of thioridazine taken in the 
previous 24 h (104 -+122, 113 ± 86, and 115"+185 mg respectively) 
and mean QTc intervals (425 -+ 29, 427 -+ 22, 411 -+ 41 ms 
respectively) were similar for the 3 groups. For the 30 subjects for 
whom data were available, QTc intervals were significantly corre- 
lated with plasma concentrations of thioridazine, T-2SO and T-SO2 
but not T-5SO. Mean thioridazine and metabolite concentrations did 
not differ significantly between EM, IM and PM subjects, although 
the numbers involved were small (15, 12 and 3 respectively). 
Conclusions: This study does not suggest that CYP2D6 genotype 
substantially affects risk of thioridazine induced QTc prolongatioi~. 
